Kinnate Biopharma Correlations
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
The current 90-days correlation between Kinnate Biopharma and Century Therapeutics is -0.15 (i.e., Good diversification). The correlation of Kinnate Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Kinnate Biopharma Correlation With Market
Good diversification
The correlation between Kinnate Biopharma and DJI is -0.07 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Kinnate Biopharma and DJI in the same portfolio, assuming nothing else is changed.
Kinnate |
Moving together with Kinnate Stock
| 0.62 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.73 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.64 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Kinnate Stock performing well and Kinnate Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kinnate Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AMAM | 3.64 | 0.64 | 0.09 | (1.36) | 4.78 | 6.05 | 29.96 | |||
| SLRN | 3.64 | (0.28) | 0.00 | (0.01) | 0.00 | 8.55 | 28.93 | |||
| WINT | 7.52 | (3.76) | 0.00 | (0.83) | 0.00 | 12.00 | 60.67 | |||
| PALI | 3.48 | (0.33) | 0.00 | 0.54 | 0.00 | 5.97 | 24.25 | |||
| IPSC | 3.97 | (0.39) | 0.00 | (0.02) | 0.00 | 7.44 | 21.67 | |||
| PASG | 5.09 | (0.25) | (0.01) | 0.02 | 5.96 | 10.00 | 25.50 | |||
| FIXX | 2.82 | 0.04 | 0.01 | 0.16 | 3.52 | 5.77 | 19.43 | |||
| GBIO | 4.07 | (1.20) | 0.00 | (0.23) | 0.00 | 9.35 | 25.48 | |||
| STOK | 2.61 | (0.33) | 0.00 | (0.13) | 0.00 | 4.68 | 21.35 | |||
| GRCL | 5.71 | 1.16 | 0.18 | 0.62 | 6.35 | 16.34 | 52.11 |
View Kinnate Biopharma Related Equities
| Risk & Return | Correlation |
Kinnate Biopharma Corporate Management
| Robert Kania | Senior Research | Profile | |
| Richard MBBS | Chief Officer | Profile | |
| Jason MD | VP Quality | Profile | |
| Neha Krishnamohan | Principal CFO | Profile | |
| Barbara Warren | VP Culture | Profile |
Still Interested in Kinnate Biopharma?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.